Efficient cytosolic delivery of therapeutic macromolecules such as genome-editing nucleases, transcription factors, and immunomodulatory proteins remains a persistent challenge in precision biomedicine. Widely adopted delivery platforms, including lipid nanoparticles, adeno-associated viruses, and extracellular vesicles, rely primarily on endocytic uptake pathways to access the interior of target cells. Quantitative evaluations of representative endocytosis-dependent systems reveal that endosomal escape is notoriously inefficient, with only one to seven percent of internalized nucleic acid cargo successfully reaching the cytosol under defined experimental conditions. Across these conventional systems, seventy to ninety-nine percent of internalized payloads remain sequestered inside endosomal compartments or undergo recycling, exocytic expulsion, or lysosomal degradation. Compounding this bottleneck, adeno-associated virus vectors are restricted by a strict packaging limit of approximately 4.7 kilobases and face neutralizing immune responses upon repeated administration, while lipid nanoparticles and extracellular vesicles suffer from formulation-dependent performance, heterogeneous cargo loading, and manufacturing hurdles. In a comprehensive review published in Materials Today Bio, researchers present an engineering framework that conceptualizes the bacterial type III secretion system as a programmable living bioactive nanomaterial capable of bypassing endocytic trafficking altogether through contact-dependent, one-step cytosolic transport.
The structural foundation of this living delivery platform is the bacterial type III secretion system injectisome, a hollow, syringe-like proteinaceous machine that spans the bacterial envelope and penetrates the target eukaryotic plasma membrane. The apparatus is organized into three distinct modular components: a membrane-embedded basal body, an intermediate channel, and an extracellular needle filament terminating in a translocon pore. The basal body is assembled from concentric SctD and SctJ inner rings paired with SctC outer rings, establishing a rigid scaffold across the bacterial inner membrane, periplasm, and outer membrane. Extending outward from this base is a hollow needle filament formed from hundreds of helically stacked SctF subunits, which measures tens of nanometers in length depending on the bacterial species, such as forty-five to fifty nanometers in Shigella, sixty nanometers in Yersinia, and up to eighty nanometers in Salmonella and Pseudomonas aeruginosa. At its distal tip, oligomerized SctB and SctE translocon subunits insert into the host membrane. Crucially, the needle possesses an inner diameter of approximately 2.5 nanometers, creating a narrow conduit that imposes a strict structural constraint: macromolecular cargo cannot pass in a folded globular conformation and must instead adopt a substantially unfolded or non-globular state during transit.
Conceptualizing this bacterial delivery architecture as a living bioactive material distinguishes the intact, replicating or metabolically active chassis from isolated, cell-free protein machines such as extracellular contractile injection systems. In native biology, diverse Gram-negative pathogens and symbionts employ type III secretion systems for host interaction programs, ranging from Salmonella SPI-1-mediated invasion and SPI-2-driven intracellular survival to Yersinia-mediated phagocytosis suppression and plant-associated symbiotic signaling. While canonical injectisomes deliver effectors directly across physical contact interfaces to bypass endosomes, alternative routes exist in nature; for example, outer membrane vesicles secreted by Salmonella Typhimurium can package virulence effectors such as SipA, SipB, SipC, and Sop proteins, yet their cellular entry relies largely on clathrin-mediated endocytosis. By focusing on canonical, membrane-anchored injectisomes within live attenuated bacteria or functional nonreplicating minicells, bioengineers leverage a multiscale system where cellular metabolic functions and nanoscale protein translocation machinery are genetically linked to direct therapeutic outcomes.
To convert this native virulence apparatus into a safe and predictable intracellular delivery platform, the authors formalize a three-module engineering framework. The first module focuses on chassis remodeling to decouple delivery capabilities from native pathogenicity and establish rigorous biological containment. Targeted virulence attenuation involves genomic deletions of major cytotoxic effectors, such as sopB in Salmonella and exoU in Pseudomonas, or the removal of systemic inflammation triggers like htrA. In Yersinia enterocolitica, multi-effector knockouts yielding the nonpathogenic delta-HOPEMT chassis leave the core export machinery intact while eliminating native cytotoxicity. To prevent environmental escape and uncontrolled bacterial proliferation, researchers integrate metabolic auxotrophies by knocking out essential biosynthetic genes such as asd, purA, or aroA, which restrict bacterial growth to environments enriched in specific metabolites or non-human nutrients like diaminopimelic acid. Dual-auxotrophy systems, including paired deletions of thyA and dapD, drastically minimize reversion risk, while genetic kill switches—such as toxin-antitoxin systems or CRISPR-based self-destruction circuits integrated into the bacterial chromosome—provide inducible fail-safes for controllable clearance.
Managing the immunological interactions of the living chassis represents another critical component of chassis design. Gram-negative bacterial vectors inherently express pathogen-associated molecular patterns, including lipopolysaccharide and flagellin, which activate toll-like receptors, while the inner-rod and needle proteins of the injectisome can directly activate NAIP-NLRC4 inflammasomes. Because therapeutic efficacy in applications like cancer immunotherapy often relies on localized immune activation, completely eliminating immunogenicity can be counterproductive. Preclinical cancer models and clinical trials with engineered bacterial therapeutics demonstrate that while localized immune stimulation drives antitumor lymphocyte recruitment, unmodulated systemic exposure risks dose-limiting toxicities such as cytokine release syndrome. To address this balance, researchers investigate biomaterial surface modifications, including cell-membrane cloaking, iron-tannic acid coatings, and encapsulation within responsive hydrogels such as gelatin methacryloyl. These surface engineering strategies reduce macrophage clearance and tune bacterial persistence in vivo, though engineering designs must ensure that surface layers do not obstruct direct physical contact between the needle filament and host membranes.
The second engineering module addresses the cargo-biomaterial interface to maximize the delivery yield of heterologous therapeutic proteins. Substrates are recruited to the injectisome via an amino-terminal engagement domain spanning fifteen to one hundred residues, which remains fused to the payload during translocation without requiring proteolytic cleavage. This terminal sequence lacks a strict consensus motif, relying instead on amphipathic properties and intrinsically disordered regions. High-throughput screening has demonstrated that secretion efficiency varies by orders of magnitude depending on signal identity; for instance, signal sequences derived from enteropathogenic Escherichia coli EspF frequently outperform alternative effectors when driving reporter translocation. For large, complex, or aggregation-prone payloads, co-expressing cognate cytosolic chaperones becomes essential. Chaperones bind specific chaperone-binding domains downstream of the secretion signal, preserving substrates in a partially unfolded, translocation-competent state while preventing premature aggregation in the bacterial cytoplasm, as demonstrated by the co-expression of SicP to dramatically enhance SptP-tagged heterologous secretion yields.
The third engineering module integrates synthetic sense-and-respond genetic circuits to confer spatiotemporal control over cargo expression and injectisome activity. Attenuated bacterial strains possess intrinsic environmental response mechanisms, such as the hypoxia-sensing Fnr transcription factor and the acid- and magnesium-responsive PhoP/PhoQ two-component system, which direct protein production toward pathological tissue niches. Synthetic biologists enhance this regulation by engineering multi-input logic gates, such as an AND gate requiring both hypoxia and a tumor-specific metabolite, thereby preventing off-target expression in physiologically hypoxic healthy organs like the liver. To achieve precise temporal control, researchers incorporate orthogonal optogenetic switches. For example, the LITESEC-T3SS architecture integrates light-oxygen-voltage domains into the cytosolic injectisome component SctQ to achieve blue-light-dependent protein translocation with micrometer-scale spatial resolution and minimal basal leakage, while light-inducible promoters like pDawn enable several-hundred-fold induction upon illumination.
A central insight emphasized in the review is the delivery-to-function conversion bottleneck: the total quantity of translocated protein does not directly reflect the abundance of biologically active molecules inside the host cell. Because the narrow needle requires cargoes to traverse in an unfolded state, translocated molecules must refold and undergo biochemical maturation within the host cytosol. To quantitatively capture these sequential events, the authors introduce a stage-resolved evaluation framework termed the functional efficacy index. Mathematically, the index is formulated as the product of three conditional efficiencies: the productive cytosolic translocation efficiency, the post-translocation conformational recovery efficiency, and the subsequent biochemical activation efficiency. When intermediate folding and activation fractions cannot be separately resolved with dedicated structural probes, their combined contribution is reported as a single post-translocation efficiency parameter, ensuring that physical translocation gains are not conflated with active therapeutic yields.
Biophysical investigations reveal that cargo compatibility with the injectisome is governed by mechanical unfoldability rather than thermodynamic stability alone. Single-molecule experiments demonstrate that natural effectors such as SptP and SopE2 exhibit remarkably low mechanical unfolding forces, whereas mechanically rigid structures such as green fluorescent protein, dihydrofolate reductase, and ubiquitin resist translocation and can clog the export apparatus. After entering the host cytosol, translocated payloads depend on cargo-specific properties and host microenvironments to regain functional conformations. Certain native effectors rely on host-assisted folding mechanisms, such as the Pseudomonas syringae effector AvrRpt2 requiring host cyclophilin ROC1 for activation, while others undergo ligand-induced folding upon binding host lipids or respond to intracellular pH and calcium gradients. Furthermore, full biological activity often necessitates post-translational modifications, cofactor binding, or proteolytic unmasking, which can be engineered using host ubiquitin-specific proteases or host-factor-dependent allosteric switches like calmodulin-dependent adenylate cyclase.
In preclinical oncology, engineered type III secretion systems exploit the natural preferential accumulation of attenuated bacteria in solid tumor microenvironments to deliver therapeutic proteins directly into malignant and immune cells. Living bacterial platforms have delivered pro-apoptotic effectors such as tumor necrosis factor-related apoptosis-inducing ligand and mitochondrially targeted Noxa, suppressing tumor progression in rodent models while sparing normal tissues. Beyond inducing direct malignant cell apoptosis, cytosolic delivery of immunomodulatory payloads triggers immunogenic cell death, promoting the release of damage-associated molecular patterns, dendritic cell maturation, and tumor-specific cytotoxic T lymphocyte responses. Furthermore, researchers have demonstrated targeted intracellular engagement in hematological malignancies, employing Yersinia injectisomes to deliver engineered monobodies that bind and inhibit the oncogenic BCR::ABL1 fusion protein directly inside chronic myeloid leukemia cells without relying on cell-surface tumor antigens.
Beyond oncology, the direct cytosolic delivery of folded-protein precursors provides opportunities in precision genome editing, cell reprogramming, and mucosal vaccination. Translocating Cre recombinase or transcription activator-like effector nucleases exceeding one hundred kilodaltons enables DNA-free, transient genomic modifications in target cells, avoiding the sustained genotoxic risks and insertional mutagenesis associated with viral vector persistence. In stem cell biology, delivering cocktails of lineage-specific transcription factors such as GATA4, MEF2C, and TBX5 via bacterial injectisomes drives the directed differentiation of human induced pluripotent stem cells into functional cardiomyocytes. For mucosal vaccination, administering engineered Salmonella strains via oral or intranasal routes targets antigen-presenting cells in gut- or mucosa-associated lymphoid tissues. Direct cytosolic injection of viral or bacterial antigens engages the major histocompatibility complex class I presentation pathway, stimulating robust antigen-specific CD8+ cytotoxic T lymphocyte responses and mucosal immunoglobulin A production, as demonstrated in challenge models for Pseudomonas aeruginosa and respiratory viral pathogens.
Despite substantial preclinical progress, clinical translation faces notable hurdles spanning biological, pharmacological, and regulatory domains. A prominent challenge is the discrepancy between preclinical rodent models and human tissue biodistribution; historically, attenuated strains such as Salmonella VNP20009 demonstrated marked tumor colonization in mice but failed to achieve significant colonization or objective clinical regression in human phase I trials. Regulatory frameworks also present complex hurdles, as current health authority guidance for live biotherapeutic products explicitly excludes oncolytic bacteria and microbial gene therapy vectors. Overcoming these barriers will require standardized potency assays that measure stage-resolved intracellular activity alongside bacterial viability, rigorous containment architectures that prevent horizontal gene transfer, and the ongoing development of minimal, genetically predictable chassis optimized for human clinical administration.
Subject of Research: Bacterial type III secretion systems repurposed as programmable living bioactive nanomaterials for intracellular delivery
Article Title: Type III secretion systems as programmable living bioactive nanomaterials: Modular engineering, quantitative metrics, and clinical translation
Article References: Xie, Y., Song, Y., Zhou, Q., Chen, Y., Chen, W., Wang, D., & Pan, J. (2026). Type III secretion systems as programmable living bioactive nanomaterials: Modular engineering, quantitative metrics, and clinical translation. Materials Today Bio, 41, Article 103851. https://doi.org/10.1016/j.mtbio.2026.103851
Image Credits: AI Generated
DOI: 10.1016/j.mtbio.2026.103851
Keywords: Type III Secretion System, Living Bioactive Nanomaterials, Intracellular Protein Delivery, Synthetic Biology, Biomaterials Engineering, Endosomal Escape, Injectisome, Functional Efficacy Index, Protein Translocation, Bacterial Chassis, Metabolic Auxotrophy, Biocontainment, Optogenetic Control, Tumor Immunotherapy, Genome Editing, Mucosal Vaccination, Nanomedicine
Cite Scienmag News
Denise Maddox. (November 21, 2026). Engineered Bacterial Type III Secretion Systems Offer Programmable Direct Intracellular Delivery. Scienmag. https://scienmag.com/engineered-bacterial-type-iii-secretion-systems-offer-programmable-direct-intracellular-delivery/
Denise Maddox. "Engineered Bacterial Type III Secretion Systems Offer Programmable Direct Intracellular Delivery." Scienmag, 21 November 2026, https://scienmag.com/engineered-bacterial-type-iii-secretion-systems-offer-programmable-direct-intracellular-delivery/. Accessed 21 November 2026.
Denise Maddox. "Engineered Bacterial Type III Secretion Systems Offer Programmable Direct Intracellular Delivery." Scienmag. November 21, 2026. https://scienmag.com/engineered-bacterial-type-iii-secretion-systems-offer-programmable-direct-intracellular-delivery/








